XPro1595 significantly improves neurodegeneration in AD trial
Treatment with XPro1595 for three months caused significant changes in neurodegeneration, synaptic function and neuroinflammation.
List view / Grid view
Treatment with XPro1595 for three months caused significant changes in neurodegeneration, synaptic function and neuroinflammation.
The first patient has been dosed with Quellor in a Phase II clinical trial, evaluating the drug for the treatment of pulmonary complications from COVID-19.